Quantum Pharmaceutical appoints commercial director

Victoria Buyer has 10 years of industry experience

Quantum Pharmaceutical, a UK-based pharmaceutical specials manufacturer, has appointed Victoria Buyer as commercial director.

With a decade’s industry experience, Buyer has previously been responsible for the growth and development of companies including GlaxoSmithKline and Alliance UniChem.

Buyer said: ‘Quantum already strives to ensure its operations are at the forefront of the marketplace – and I’m determined to build on its strong foundations and forge links with new partners while reinforcing collaboration with our loyal customer network.’

You may also like

Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

How CDMOs can set a new gold standard when it comes to going green

Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
Research & Development

Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research

The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
Manufacturing

ACG expands global footprint with new capsule manufacturing facility in Thailand

New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
Manufacturing

Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary

The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
Manufacturing

£20m Scottish oligonucleotide manufacturing innovation centre now under construction

The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence
Subscribe now